ACET ADICET BIO INC revenue, earnings and financials
For the quarter ended June 30, 2026, ADICET BIO INC reported revenue of n/a, net income of −$21.4M and diluted EPS of −$1.99; for the fiscal year ended December 2025 revenue was n/a.
ACET annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$122M, net income −$117M (margin n/a), EPS −$16.95
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$128M, net income −$117M (margin n/a), EPS −$21.33
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$152M, net income −$143M (margin n/a), EPS −$3.31
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income −$72.6M, net income −$69.8M (margin n/a), EPS −$1.70
- Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$61.4M, net income −$62.0M (margin n/a), EPS −$2.00
ACET quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$21.4M, EPS −$1.99
- Quarter ended Mar 31, 2026: revenue n/a, net income −$20.2M, EPS −$1.88
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$30.5M, EPS −$6.22
- Quarter ended Sep 30, 2025: revenue n/a, net income −$26.9M, EPS −$0.29
- Quarter ended Jun 30, 2025: revenue n/a, net income −$31.2M, EPS −$5.48
- Quarter ended Mar 31, 2025: revenue n/a, net income −$28.2M, EPS −$4.96
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$28.7M, EPS −$20.31
- Quarter ended Sep 30, 2024: revenue n/a, net income −$30.5M, EPS −$0.34
- Quarter ended Jun 30, 2024: revenue n/a, net income −$29.9M, EPS −$0.33
- Quarter ended Mar 31, 2024: revenue n/a, net income −$28.0M, EPS −$0.35
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$29.5M, EPS −$0.68
- Quarter ended Sep 30, 2023: revenue n/a, net income −$49.9M, EPS −$1.16
- Quarter ended Jun 30, 2023: revenue n/a, net income −$32.4M, EPS −$0.75
- Quarter ended Mar 31, 2023: revenue n/a, net income −$30.9M, EPS −$0.72
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$29.9M, EPS −$0.71
- Quarter ended Sep 30, 2022: revenue n/a, net income −$22.0M, EPS −$0.53
- Quarter ended Jun 30, 2022: revenue n/a, net income −$22.5M, EPS −$0.56
- Quarter ended Mar 31, 2022: revenue n/a, net income $4.62M, EPS $0.10
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$15.8M, EPS −$0.40
- Quarter ended Sep 30, 2021: revenue n/a, net income −$14.0M, EPS −$0.44
ACET cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$95.2M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$92.4M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$93.7M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$44.8M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$51.1M, share buybacks n/a
ACET balance sheet
- Jun 30, 2026: cash $33.1M, total assets $148M, total liabilities $28.0M, shareholders' equity $120M
- Mar 31, 2026: cash $36.2M, total assets $169M, total liabilities $29.3M, shareholders' equity $140M
- Dec 31, 2025: cash $38.9M, total assets $192M, total liabilities $33.1M, shareholders' equity $159M
- Sep 30, 2025: cash $29.1M, total assets $140M, total liabilities $31.3M, shareholders' equity $109M
- Jun 30, 2025: cash $34.7M, total assets $163M, total liabilities $29.6M, shareholders' equity $133M
- Mar 31, 2025: cash $28.1M, total assets $191M, total liabilities $29.8M, shareholders' equity $161M
- Dec 31, 2024: cash $56.5M, total assets $220M, total liabilities $33.6M, shareholders' equity $187M
- Sep 30, 2024: cash $105M, total assets $246M, total liabilities $34.4M, shareholders' equity $212M
Is ACET profitable?
No. ADICET BIO INC lost $99.0M over the last four quarters.
What is ACET's EPS?
Diluted earnings per share over the last four quarters were −$10.38; −$1.99 in the latest quarter.